42个种系PALB2剪接位点变异的剪接预测、小基因分析与ACMG-AMP临床分类
PALB2 loss-of-function variants confer high risk of developing breast cancer. Here we present a systematic functional analysis of PALB2 splice-site variants detected in approximately 113,000 women in the large-scale sequencing project Breast Cancer After Diagnostic Gene Sequencin…
要点
- 35个PALB2剪接位点变异显示剪接异常,23个被分类为致病/可能致病。
- 3个±1,2变异因产生意义不明的框内转录本或全长转录本被归为VUS。
- 小基因功能测定结合ACMG-AMP分类可辅助PALB2剪接变异解读。
核心结论
- 42个PALB2剪接位点变异中35个导致剪接异常,23个根据ACMG-AMP分类为致病/可能致病。
- 三个±1,2变异(c.49-2A>T、c.108+2T>C、c.211+1G>A)因产生显著量的框内转录本或小基因全长转录本被归类为意义不明变异。
研究设计与样本
- 选取42个变异,构建包含外显子1-12的三个剪接报告小基因,通过定点突变引入变异并在MCF-7/MDA-MB-231细胞中测定。
主要发现
- 35个变异观察到剪接异常,其中23个显示无或极少量的预期全长转录本。
- 鉴定出超过30种变异诱导的转录本,其中23种预测会截短PALB2蛋白。
- 23个变异被分类为致病/可能致病。
关键数值与推荐
- 采用内部调整的ACMG-AMP变异分类方案进行致病性判读。
- 三个±1,2变异因产生显著量的框内转录本(对PALB2蛋白功能影响未知)或小基因全长转录本而被分类为意义不明变异。
临床怎么用
- 对于PALB2剪接位点变异,可结合MaxEntScan预测与小基因功能测定辅助ACMG-AMP分类。
- 产生框内转录本或全长转录本的±1,2变异需谨慎判读,可能归为意义不明变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PALB2 loss-of-function variants confer high risk of developing breast cancer. Here we present a systematic functional analysis of PALB2 splice-site variants detected in approximately 113,000 women in the large-scale sequencing project Breast Cancer After Diagnostic Gene Sequencing (BRIDGES; https://bridges-research.eu/). Eighty-two PALB2 variants at the intron-exon boundaries were analyzed with MaxEntScan. Forty-two variants were selected for the subsequent splicing functional assays. For this purpose, three splicing reporter minigenes comprising exons 1-12 were constructed. The 42 potential spliceogenic variants were introduced into the minigenes by site-directed mutagenesis and assayed in MCF-7/MDA-MB-231 cells. Splicing anomalies were observed in 35 variants, 23 of which showed no traces or minimal amounts of the expected full-length transcripts of each minigene. More than 30 different variant-induced transcripts were characterized, 23 of which were predicted to truncate the PALB2 protein. The pathogenicity of all variants was interpreted according to an in-house adaptation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) variant classification scheme. Up to 23 variants were classified as pathogenic/likely pathogenic. Remarkably, three ±1,2 variants (c.49-2A>T, c.108+2T>C, and c.211+1G>A) were classified as variants of unknown significance, as they produced significant amounts of either in-frame transcripts of unknown impact on the PALB2 protein function or the minigene full-length transcripts. In conclusion, we have significantly contributed to the ongoing effort of identifying spliceogenic variants in the clinically relevant PALB2 cancer susceptibility gene. Moreover, we suggest some approaches to classify the findings in accordance with the ACMG-AMP rationale. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd on behalf of The Pathological Society of Great Britain and Ireland.
引用
- Valenzuela-Palomo A, Bueno-Martínez E, Sanoguera-Miralles L, et al. Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants. J Pathol. 2021. PMID: 34846068. doi:10.1002/path.5839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。